A survey of current clinical practice in permanent and temporary prostate brachytherapy: 2010 update

Brachytherapy

Volumn 11, Issue 4, 2012, Pages 299-305

  Buyyounouski, Mark K ^a   Davis, Brian J ^b   Prestidge, Bradley R ^c   Shanahan, Thomas G ^d   Stock, Richard G ^e   Grimm, Peter D ^f   Demanes, D Jeffrey ^g   Zaider, Marco ^h   Horwitz, Eric M ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

^c South Texas Radiation Therapy Associates   (United States)

^d MEMORIAL HEALTH SYSTEM   (United States)

^e MOUNT SINAI MEDICAL CENTER   (United States)

^f Prostate Cancer Treatment Center   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

High dose rate brachytherapy; Low dose rate brachytherapy; Prostate cancer

Indexed keywords

BICALUTAMIDE; CYPROTERONE ACETATE; DUTASTERIDE; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL PRACTICE; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HEALTH SURVEY; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; RESIDENCY EDUCATION; TRANSURETHRAL RESECTION;

BRACHYTHERAPY; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 84862576935     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2011.12.012     Document Type: Article

References (18)

1. Crook J., Borg J., Evans A., et al. 10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: Results for 1,100 patients. Int J Radiat Oncol Biol Phys 2010, 80:1323-1329.
2. Taira A.V., Merrick G.S., Butler W.M., et al. Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2010, 79:1336-1342.
3. Sylvester J.E., Grimm P.D., Wong J., et al. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience. Int J Radiat Oncol Biol Phys 2010, 81:376-381.
4. Sylvester J.E., Grimm P.D., Blasko J.C., et al. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 2007, 67:57-64.
5. Ragde H., Elgamal A.A., Snow P.B., et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 1998, 83:989-1001.
6. Lawton C.A., DeSilvio M., Lee W.R., et al. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05). Int J Radiat Oncol Biol Phys 2007, 67:39-47.
7. Hsu I.C., Bae K., Shinohara K., et al. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: Preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys 2010, 78:751-758.
8. Lee W.R., Bae K., Lawton C., et al. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: Analysis of Radiation Therapy Oncology Group study 0019. Cancer 2007, 109:1506-1512.
9. Feigenberg S.J., Lee W.R., Desilvio M.L., et al. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. Int J Radiat Oncol Biol Phys 2005, 62:956-964.
10. Prestidge B.R., Prete J.J., Buchholz T.A., et al. A survey of current clinical practice of permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys 1998, 40:461-465.
11. Prete J.J., Prestidge B.R., Bice W.S., et al. A survey of physics and dosimetry practice of permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys 1998, 40:1001-1005.
12. American Joint Committee on Cancer Prostate. AJCC Cancer Staging Manual 2002, 309-316. Lippincott Raven, Philadelphia, PA. F.L.P.D. Greene, I.D. Fleming, A.G. Fritz, C.M. Balch, D.G. Haller, M. Morrow (Eds.).
13. Frank S.J., Grimm P.D., Sylvester J.E., et al. Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in the United States. Brachytherapy 2007, 6:2-8.
14. Nag S., Beyer D., Friedland J., et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999, 44:789-799.
15. Beyer D., Nath R., Butler W., et al. American brachytherapy society recommendations for clinical implementation of NIST-1999 standards for (103)palladium brachytherapy. The clinical research committee of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 2000, 47:273-275.
16. Rivard M.J., Butler W.M., Devlin P.M., et al. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103. Brachytherapy 2007, 6:34-37.
17. Davis B., Horwitz E., Lee W., et al. American Brachytherapy Society guidelines for transrectal ultrasound guided permanent prostate brachytherapy. Brachytherapy 2012.
18. Frank S.J., Arterbery V.E., Hsu I.C., et al. American College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate cancer. Brachytherapy 2011, 10:357-362.